Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma

Journal of Clinical Oncology

Volumn 23, Issue 1, 2005, Pages 105-112

  Worden, Francis P ^a   Taylor, Jeremy M G ^a   Biermann, Janet S ^a   Sondak, Vernon K ^a   Leu, Kirstin M ^a   Chugh, Rashmi ^a   McGinn, Cornelius J ^a   Zalupski, Mark M ^a   Baker, Laurence H ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; INCIDENCE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CHILD; COMPARATIVE STUDY; DRUG TOLERANCE; MIDDLE AGED; MORTALITY; SARCOMA; SOFT TISSUE TUMOR; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANEMIA; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DOXORUBICIN; DRUG TOLERANCE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEUTROPENIA; PROGNOSIS; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 16644397432     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.108     Document Type: Article

References (32)

1. Biermann JS, Baker LH: The future treatment of sarcoma. Semin Oncol 24:592-597, 1997
2. Keohan ML, Taub RN: Chemotherapy for advanced sarcoma: Therapeutic decisions and modalities. Semin Oncol 24:572-579, 1997
3. Antman KH, Crowley J, Balcerzak S, et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11:1276-1285, 1993
4. Edmonson JH, Ryan LM, Blum RH, et al: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced tissue sarcomas. J Clin Oncol 11:1269-1275, 1993
5. Santoro A, Tursz T, Mouridsen H, et al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537-1545, 1995
6. Steward WP, Verweiji J, Somers R, et al: Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 11:15-21, 1993
7. Le Cesne A, Judson I, Crowther D, et al: Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18:2676-2684, 2000
8. O'Bryan RM, Baker LH, Gottlieb JE, et al: Dose response evaluation of adriamycin in human neoplasia. Cancer 39:1940-1948, 1977
9. Antman KH, Ryan L, Elias AD, et al: Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 7:126-131, 1989
10. Benjamin RS, Legha SS, Patel SR, et al: Single-agent ifosfamide studies in sarcomas of soft-tissue and bone: The M.D. Anderson experience. Cancer Chemother Pharmacol 31:S174-S179, 1993
11. Patel SR, Vadhan-Raj S, Papadopolous N, et al: High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies-Dose-response and schedule dependence. J Clin Oncol 15:2378-2384, 1997
12. van Ooserom AT, Mouridsen HT, Nielsen OS, et al: Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 38:2397-2406, 2002
13. Therasse P, Arbuck S, Eisenhauer E, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
14. Zalupski M, Baker LH: Ifosfamide. J Natl Cancer Inst 80:556-566, 1988
15. Schutte J, Dombernowsky P, Mouridsen HT, et al: Ifosfamide plus adriamycin in previously untreated patients with advanced STS: Final results of a phase II trial of the EORTC/STBSG. Eur J Cancer 26:558-561, 1990
16. Patel SR, Vadhan-Raj S, Burgess MA, et al: Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 21:317-321, 1998
17. Toma S, Palumbo R, Canavese G, et al: Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. Cancer Chemother Pharmacol 31:S222-S227, 1993 (suppl 2)
18. Chevallier B, Leyvraz S, Olivier JP, et al: Epirubicin and ifosfamide in advanced soft tissue sarcoma: A phase II study. Cancer Invest 11:135-139, 1993
19. Palumbo R, Neumaier C, Cosso M, et al: Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: A phase II study. Eur J Cancer 35:66-72, 1999
20. Mouridsen HT, Bastholt L, Somers R, et al: Adriamycin versus epirubicin in advanced STS: A randomized phase II/III study of the EORTC/STBSG. Eur J Cancer 33:220-225, 1995
21. Palumbo R, Palmeri S, Antimi M, et al: Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pre-treated soft tissue sarcomas. Ann Oncol 8:1159-1162, 1997
22. Le Cesne A, Antoine E, Spielman M, et al: High dose ifosfamide: Circumvention of resistance to standard dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 13:1600-1608, 1995
23. Nielsen OS, Dombernowsky P, Mouridsen H, et al: High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas: A study of the EORTC Soft Tissue and Bone Sarcoma Group. Br J Cancer 78:1634-1639, 1998
24. Nielsen OS, Judson I, van Hoesel Q, et al: Effect of high-dose ifosfamide in advanced soft tissue sarcomas: A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 36:61-67, 2000
25. Borden EC, Amato DA, Rosenbaum CH, et al: Randomized comparison of three Adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 5:840-850, 1987
26. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
27. Heinrich M, Corless C, Demetri G, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349, 2003
28. van Oosterom A, Judson I, Verweij J, et al: Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: A report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38:83-87, 2002
29. Sarcoma Meta-Analysis Collaboration: Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. Lancet 350:1647-1654, 1997
30. Frustaci S, Gherlinzoni F, De Paoli A, et al: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial. J Clin Oncol 19:1238-1247, 2001
31. Gortzak E, Azzarelli A, Buesa J, et al: A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 37:1096-1103, 2001
32. Buesa J, Lopez-Pousen A, Anton A, et al: Phase II trial of first line HD-IF in advanced STS. Proc Am Soc Clin Oncol 16:498a, 1998 (abstr 1793)